Clofibrate Capsules

This product is a lipid-regulating drug of clofibric acid derivatives. It achieves the purpose of lowering blood lipids by reducing very low-density lipoproteins. However, its mechanism of lowering blood lipids is not fully understood. It may involve inhibiting the release of liver lipoproteins (especially very low-density lipoproteins) and cholesterol synthesis, changing liver triglyceride synthesis, enhancing the action of lipoprotein esterase, increasing steroid secretion and excretion from feces, and increasing the clearance of triglycerides (very low-density lipoproteins) in the circulation. Animal experiments have shown that long-term and large-scale use of this product can lead to the occurrence of benign or malignant tumors. If 1-2 times the maximum human dose is used for a long time in mice and rats (counted by body surface area mg/m2), the incidence of benign and malignant liver tumors will increase compared with the control group.

The chemical name of this product is: 2-methyl-2-(4-chlorophenoxy)ethyl propionate. Its structural formula is: Molecular formula: C12H15ClO3 Molecular weight: 242.70

This product is a soft capsule.

Hyperlipidemia, its triglyceride-lowering effect is more obvious than its cholesterol-lowering effect. In view of the potential carcinogenicity of this product to humans, its use should be strictly limited to the specified range of indications, and the drug should be discontinued in time if the therapeutic effect is not obvious.

The usual oral dose for adults is 0.25-0.5g at a time, 3-4 times a day. In order to reduce gastrointestinal reactions, this product should be taken with food. It is advisable to use a small dose at the beginning and then gradually increase it. However, the prescribed dose should be reached within the first month of treatment, and it is best to adopt a decreasing method when stopping the drug. Sometimes the effect is not significant within the first month of taking the drug, but it can be effective if it is continued. It needs to be taken for a long time. After stopping the drug, serum cholesterol and triglycerides may rise or even exceed the original level, so diet control therapy should be adopted and blood lipids should be monitored until it is stable. If the treatment is ineffective for 3 months, the drug should be stopped, but the treatment of nodular xanthomas may take a year. Patients with liver and kidney dysfunction need to reduce the dosage of the drug.

1. Long-term use of this product may aggravate cholelithiasis and gallbladder disease and require surgery. 2. There is an increased risk of peripheral vascular disease, pulmonary embolism, thrombophlebitis, angina pectoris, arrhythmia and intermittent claudication. 3. Chest pain, shortness of breath, and angina pectoris are occasionally seen clinically; blood creatine phosphokinase and serum aminotransferase increase, but not due to myocardial infarction. 4. Common adverse reactions in clinical practice include diarrhea and nausea; less common adverse reactions include: ① arrhythmia; ② leukopenia or anemia with fever, chills, hoarseness, back pain, and dysuria; ③ hematuria, oliguria, and edema of the feet and lower limbs due to renal toxicity. 5. Adverse reactions that are rare in clinical practice but require attention when they persist include: influenza-like syndrome (myalgia, fatigue, common in patients with kidney disease, and often accompanied by creatine phosphokinase and

1. Patients who are allergic to clofibrate are contraindicated; 2. Patients with primary biliary cirrhosis are contraindicated because this product can promote increased cholesterol excretion and increase the already high cholesterol level; 3. Patients with liver and kidney dysfunction are contraindicated because taking this product in patients with renal dysfunction may cause rhabdomyolysis and severe hyperkalemia.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. When this product is used simultaneously with anticoagulants, its anticoagulant effect can be significantly increased. Therefore, the prothrombin time should be measured frequently to adjust the dosage of anticoagulants to keep it within the ideal range and prevent the occurrence of bleeding complications. 2. When this product is used simultaneously with furosemide, the effects of both drugs can be increased. It can cause myopathy, muscle stiffness and diuresis, especially for patients with hypoproteinemia. 3. This product can replace the protein binding sites of acidic drugs such as phenytoin sodium or tolbutamide. Therefore, when used in combination with the above drugs or other drugs with high protein binding rates, attention should be paid to increasing the efficacy of the latter, such as using it in combination with oral hypoglycemic tolbutamide to enhance its hypoglycemic effect. 4. This product may cause myopathy or rhabdomyolysis. Therefore, it should be avoided as much as possible in combination with HMG-CoA reductase inhibitors such as pravastatin and simvastatin to reduce the risk of severe muscle toxicity of both drugs.

Keep away from light and store in a sealed container.

0.5 g

24 months